Progenics Pharmaceuticals Inc (PGNX)

8.96
0.16 1.82
NASDAQ : Health Care
Prev Close 8.80
Open 8.88
Day Low/High 8.72 / 8.98
52 Wk Low/High 3.61 / 11.15
Volume 765.97K
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 70.05M
Market Cap 627.66M
EPS -0.60
P/E Ratio 56.00
Div & Yield N.A. (N.A)

Latest News

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHP, ARCX, ATNI, HTGC, MGM, PGNX, PGRE, SGMS, SYF, WABC Downgrades: ABDC, ARCC, ARII, BOJA, CTLT, FSM, GEL, H, KMPR, LBTYA, LBTYB, LBTYK, TSCO Initiations: PEN, PSTG Read on to get TheStreet Quant Ratings' detailed report:

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Provides Non-Dilutive Funding to Advance Late-Stage Oncology Portfolio

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options

Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options

Investors considering a purchase of Progenics Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

3 Stocks for Growth in 2017

3 Stocks for Growth in 2017

BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

RELISTOR Tablets FDA-Approved for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Short Interest Increases 10% For PGNX

Short Interest Increases 10% For PGNX

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 930,934 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 10,136,448, an increase of 10.11% since 07/29/2016.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Company Eligible to Receive Up to $200 Million of Sales Milestone Payments and Ongoing Sales Royalties

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "perilous reversal" (up big yesterday but down big today) candidate